# Parabilis Medicines Inc. (PBLS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $40.42, market value $5.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Parabilis Medicines Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -2.5%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 882.9%**. A 882.9% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): 9.9%**. Earnings per share rose 9.9%.

## Financial health
- **Current ratio: 0.52** (quick 0.52). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Parabilis Medicines Inc. does not currently pay a dividend, but it returned -1.4% of its market value through buybacks over the last year.

## Price and momentum
- **From 52-week high: -2.6%** (64.9% above the low). Trading within 5% of its 52-week high.
- **RSI (14-day): 64**. An RSI of 64 is neutral.
- **Beta (1 yr): -0.57** (volatility 65%). Beta of -0.57 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PBLS · Page: https://foliofundamentals.com/stocks/pbls

Not investment advice.